Oligodendroglial tumor chemotherapy using "decreased-dose-intensity" PCV: a Singapore experience.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16434664.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors propose "decreased-dose-intensity" PCV (procarbazine, lomustine [CCNU], and vincristine) chemotherapy for Asian patients with oligodendroglial tumors. In this study, all seven patients with oligodendroglioma (OD) and eight with anaplastic oligodendroglioma (AO) had objective responses or stable disease. Median progression-free survival was greater than 29 months (OD) and 36.5 months or greater (AO); 86% of patients with OD and 63% with AO remain progression-free. Twenty-four Common Toxicity Criteria Grade 3/4 adverse events were noted.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Asian People
- Brain Neoplasms
- Oligodendroglioma